Clinical trials: Non-GCB/ABC Diffuse Large B-Cell Lymphoma
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation…
- Trial name
- NCT05319028
- Testing
- Mivavotinib
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Calithera Biosciences, Inc
Non-Hodgkin's Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary…
- Trial name
- NCT06667687
- Testing
- ABBV-291
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 21 people
- Sponsor
- AbbVie
Lymphoid Malignancies
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics…
- Trial name
- NCT01705847
- Testing
- GS-9820
- Where
- 4 sites in Netherlands
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Non-GCB/ABC Diffuse Large B-Cell Lymphoma
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients
- Trial name
- NCT04835870
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- 16 sites in China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, Diffuse Large-Cell B-cell, Diffuse, Large B-cell Lymphoma
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Background: MLN4924 is an experimental cancer drug. It may help kill lymphoma cells and make them more sensitive to chemotherapy. EPOCH R is a combination chemotherapy drug.
- Conditions
- Lymphoma, Diffuse Large-Cell B-cell, Diffuse, Large B-cell Lymphoma, Lymphoma, Diffuse Large-Cell, Large-Cell Lymphoma, Diffuse
- Trial name
- NCT01415765
- Testing
- MLN4924, Etoposide, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
B-cell Non Hodgkin Lymphoma
A Study of ARC-02 in B-cell NHL
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
- Trial name
- ABLATE-101 (NCT07691606)
- Testing
- ARC-02, Rituximab
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 140 people
- Sponsor
- Taiho Oncology, Inc.